CHRS Coherus BioSciences Inc.

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

A webcast replay will be available on following the conclusion of the live conference call.

Conference Call Information

When: Wednesday, November 6, 2024, starting at 5:00 p.m. Eastern Time

To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call:

Webcast:

The press release with the third quarter 2024 financial results and related materials will be available at before the start of the conference call.

A live and archived webcast will be available on the “Investors” section of the Coherus website at /events-presentations.

Please dial in 15 minutes early to ensure a timely connection to the call.

Disclosure Information

Coherus uses the website to disclose material non-public information and comply with its disclosure obligations under Regulation FD. 

Coherus Contact Information

Investors:

Jodi Sievers, Vice President, Investor Relations and Corporate Communications



EN
30/10/2024

Underlying

CHRSCoherus BioSciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coherus BioSciences Inc.

 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Completes Strategic Transformation to Coherus Oncology, Focusi...

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines. “The field of cancer immunotherapy has been reinvigorated by the promise and power of combination therapies. Coherus Oncology has the expertise and ...

May 30, 2025 1 EN
Free Trial
CHRS Coherus BioScie...

Coherus Biosciences Inc: 1 director

A director at Coherus Biosciences Inc sold 99,988 shares at 0.739USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

CHRS COHERUS BIOSCIENCES INC.
05/29/25 May 29, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Announces Clinical Collaboration with STORM Therapeutics to Ev...

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) – First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor – REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, ...

May 27, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus BioSciences Reports First Quarter 2025 Financial Results and P...

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update – Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million ...

May 12, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on following the conclusion of the live conference call. Conference Call Inf...

May 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch